Subscribe in a reader

Cambridge MedChem Consulting

MMV call for proposals

MMV welcomes proposals in the following three areas

1. Compounds addressing the key priorities of the malaria eradication agenda

Novel families of molecules in the hit-to-lead or lead optimization stages are sought without G6PD deficiency liabilities that either:

  • Kill or reactivate hypnozoites for use as part of a P. vivax radical cure; or
  • Have activity against sexual stage V gametocytes and evidence of transmission blocking in SMFA.

2. Compounds with activity against asexual liver and/or blood stages

Novel chemical series with EC50<500nM and which have one or more of the following key features:

  • A known, novel mechanism of action;
  • An inability to select resistant mutants in vitro;
  • Activity at more than one life-cycle stage;
  • A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy.
  • For advanced series, we are seeking novel compounds with, ideally, a predicted human half-life >100h and a predicted oral single human dose <500mg or an i.m. dose that can be administered in <1mL and sufficient for up to 3 months’ protection in humans.

3. Novel approaches for screening

  • To help identify new phenotypic and/ or target based hits, as well as confirm activity of MMV compounds on all human malaria asexual blood stages, new screening proposals are sought .